Colorectal cancer with RAS wild type can be effectively treated with cetuximab, while it is known that patients with a K-RAS or N-RAS mutation do not respond to anti-EGFR treatment (van Cutsem et al., 2011). Here, EGFR is linked to colorectal cancer.